NasdaqGS - Nasdaq Real Time Price • USD
ORIC Pharmaceuticals, Inc. (ORIC)
As of 11:07 AM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 9 | 9 | 9 | 9 |
| Avg. Estimate | -0.41 | -0.43 | -1.72 | -1.93 |
| Low Estimate | -0.44 | -0.45 | -2.1 | -2.19 |
| High Estimate | -0.38 | -0.42 | -1.63 | -1.58 |
| Year Ago EPS | -0.5 | -0.44 | -1.96 | -1.72 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 7 | 7 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.57 | -0.46 | -0.49 | -0.44 |
| EPS Actual | -0.5 | -0.44 | -0.49 | -0.37 |
| Difference | 0.07 | 0.02 | 0 | 0.07 |
| Surprise % | 12.30% | 4.30% | 0.00% | 15.90% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.41 | -0.43 | -1.72 | -1.93 |
| 7 Days Ago | -0.41 | -0.43 | -1.72 | -1.93 |
| 30 Days Ago | -0.43 | -0.45 | -1.83 | -1.98 |
| 60 Days Ago | -0.42 | -0.45 | -1.75 | -2.01 |
| 90 Days Ago | -0.55 | -0.57 | -2.16 | -2.16 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 6 | 4 | 8 | 4 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ORIC | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 18.00% | -- | -- | 8.00% |
| Next Qtr. | 2.30% | -- | -- | 12.40% |
| Current Year | 12.20% | -- | -- | 5.60% |
| Next Year | -12.20% | -- | -- | 12.60% |
| Next 5 Years (per annum) | -- | -- | -- | 11.14% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Citigroup: Buy to Buy | 5/7/2024 |
| Maintains | JP Morgan: Overweight to Overweight | 3/27/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/21/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 3/12/2024 |
| Reiterates | Wedbush: Outperform to Outperform | 3/12/2024 |
| Reiterates | Baird: Outperform to Outperform | 3/12/2024 |
Related Tickers
KROS Keros Therapeutics, Inc.
51.98
-0.57%
ERAS Erasca, Inc.
2.0050
+1.78%
PASG Passage Bio, Inc.
1.2601
-4.54%
NRIX Nurix Therapeutics, Inc.
16.53
-0.39%
MLYS Mineralys Therapeutics, Inc.
12.94
-0.46%
RLAY Relay Therapeutics, Inc.
6.48
-2.41%
LRMR Larimar Therapeutics, Inc.
7.35
-0.41%
BDTX Black Diamond Therapeutics, Inc.
4.8800
+0.21%
ZNTL Zentalis Pharmaceuticals, Inc.
11.84
-1.95%
OLMA Olema Pharmaceuticals, Inc.
9.56
-2.90%